Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

You may be eligible if

• Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria:
• * Stage I-IV disease
• * No morphologically unclassifiable disease
• Meets 1 of the following criteria:
• * Mixed cellularity
• * Lymphocytic depletion (LD)
• * LD, diffuse fibrosis
• * LD, reticular
• * Lymphocyte predominance (LP)
• * LP, diffuse
• * LP, nodular
• * Nodular sclerosis (NS)
• * NS, cellular phase
• * NS, lymphocytic predominance
• * NS, mixed cellularity
• * NS, LD
• * Not otherwise specified
• Primary refractory disease OR disease in first relapse, except for the following:
• * Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy
• * Patients on the observation-only arm of protocol COG-AHOD0431
• Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)
• Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met:
• * Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)
• * Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)
• Karnofsky performance status (PS) 60-100% (for patients \> 16 years of age) OR Lanksy PS 60-100% (for patients =\< 16 years of age)
• Life expectancy \>= 2 months
• Absolute neutrophil count \>= 1,000/mm\^3
• Platelet count \>= 75,000/mm\^3 (transfusion independent) (for patients with no bone marrow involvement)
• Creatinine =\< 1.5 times upper limit of normal (ULN)
• Creatinine clearance or radioisotope glomerular filtration rate \>= 70 mL/min/1.73 m\^2
• AST and ALT =\< 2.5 times ULN
• Bilirubin =\< 1.5 times ULN
• Shortening fraction \>= 27% by echocardiogram OR LVEF \>= 50% by gated radionuclide study
• No CNS toxicity \> grade 2
• No serious intercurrent illnesses
• No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs
• No peripheral neuropathy \> grade 1
• No known hypersensitivity to bortezomib, boron, or mannitol
• No other concurrent chemotherapy or immunomodulating agents (including steroids)
• * Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions
• * No dexamethasone or aprepitant as an antiemetic
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Recovered from prior therapy
• No prior bortezomib or other proteasome inhibitors
• At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)
• More than 14 days since prior investigational drugs
• No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants
• * Benzodiazepine or gabapentin allowed